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Effects of HBV and HCV infection on oxidative stress 
and inflammation in hemodialysis patients
Abstract
Background and purpose: Chronic renal failure is a syndrome char-
acterized by progressive and irreversible loss of nephrons depending on 
various diseases. Especially infection such as HBV and HCV  is among the 
major causes of mortality and morbidity in hemodialysis patients.In the 
present study we aimed to determine the levels of 3-nitrotyrosine (3-NT), 
TNF-like weak inducer of apoptosis (TWEAK) and heat shock protein 
(HSP70) in chronic renal failure patients diagnosed with HBV, HCV and 
non-hepatitis undergoing hemodialysis treatment.  
Materials and methods: Samples of 235-patients receiving hemodi-
alysis treatment and 25-healthy individuals were included in the study. 
Firstly, HBV and HCV positivity were diagnosed by serological Enzyme-
Linked ImmunuSorbent Assay (ELISA) method. Then, 3-NT levels were 
determined using High-Performance Liquid Chromatography (HPLC), 
while TWEAK and HSP70 were determined using high sensitivity ELISA. 
The numbers of patients used in the studies were determined according to 
statistical power analysis. 
Results: The values of 3-NT and HSP70 were found to be significantly 
higher non-hepatitis patients, HBV and HCV patients receiving hemodi-
alysis treatment to compared with the control group (p‹0.05). Concentration 
of TWEAK in non-hepatitis and HBV patients receiving hemodialysis 
therapy was found to be significantly higher to compared with the control 
group (p‹0.05). However, unlike the other two groups, an increase in the 
TWEAK of HCV patients on post-dialysis was determined. 
Conclusions: To prevent the increase of inflammation and oxidative 
stress in hemodialysis patients or to keep it under control, investigating cer-
tain parameters such as TWEAK, 3-NT and HSP70 from time to time is 
of great importance in terms of minimizing the level of risk for many dis-
eases such as cardiovascular diseases. Infection also increases the burden on 
oxidative stress and immunity system in these patients. 
INTRODUCTION
Some changes occur in several clinical and laboratory findings in patients due to loss of in the kidneys. These findings increase based 
on how progressive the loss of function is and they are classified into 
four stages (1). Terminal period, the fourth one, is the uremia and dur-
ing this period, patients need renal replacement therapies such as dialy-
sis or transplantation. Hemodialysis patients in the terminal stage are 
quite susceptible to various infections, particularly viral infections, par-
ticularly (2). Hepatitis B (HBV) and hepatitis C (HCV) viruses which 
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are major health problems in all societies are also seen 
frequently in hemodialysis patients. everal factors are 
known to be associated with increased risk of HBV and 
HCV infections. Duration on HD is well recognized as 
a important predisposing factor for HBV and HCV. It is 
estimated that over two billion people are infected with 
HBV on the worldwide (3). Compared with other viruses 
transmitted by blood, HBV is highly contagious (5). 
However, approximately 1.75 million people were newly 
infected with HVC in 2015, thus bringing the global to-
tal of people living with HCV to 71 million (4–6). In 
studies conducted in recent years, it has been reported 
that HBV and HCV infections have a high incidence in 
patients undergoing chronic hemodialysis therapy (2, 
7–10). This is both due to the weak immune systems and 
a large number of parenteral interventions during treat-
ment (7, 8). Especially, they do not respond sufficiently to 
vaccinations thymus-dependent antigens, such as HBV 
(1, 9–11). The most important ways of transmission of 
HCV in dialysis units are contaminated materials, insuf-
ficiently trained cleaning staff and vials being used on 
multiple patients (12). However, it is not known what 
precautions are taken to protect these patients from viral 
agents such as HBV and HCV (2). The longer the dura-
tion of dialysis in hemodialysis patients, the higher the 
frequency of HBV and HCV incidence rises significantly 
in the same way (13– 15). A major chronic reduction in 
antioxidant systems and an increase in the formation of 
oxygen free radicals are both encountered in dialysis pa-
tients and in patients with hepatitis (16). It is observed 
that free oxygen radicals are overproduced in organisms, 
while antioxidant mechanism remains inadequate, dis-
rupting the balance which means that oxidative stress 
occurs. Studies in recent years indicate that the increased 
oxygen free radicals and lipid peroxidation play a part in 
the development of many diseases (17–19). Normally an-
tioxidant defense and reactive oxygen species in the hu-
man body are in balance. Intensive production of reactive 
oxygen species or the decline of antioxidant defense cre-
ates oxidative stress by causing structural and functional 
changes in biomolecules (19, 20). Studies conducted so 
far suggest, it has been seen that hemodialysis therapy 
applied for end-stage chronic renal failure patients leads 
to increased oxidative stress (21–23). In recent years, 3-ni-
trotyrosine (3-NT) is used as a marker to evaluate poten-
tial cytotoxic effects of NO in the organism. Peroxynitrite 
(NO–) is a cytocidal derivative occurring as a result of 
reactions of with nitric oxide (NO) and O2 in the living 
beings (24). Another important marker for oxidative stress 
and immunity is the TNF-like weak inducer of apoptosis 
(TWEAK), a member of the TNF family. It has many 
functions similar to TNF-a. TWEAK in cytokine fam-
ily is stimulates apoptosis, while at the same time it in-
duces inflammation and cell growth. Another marker 
exhibiting an increase under stress heat shock protein 
HSP70. The increase occurring in HSP70 offers protec-
tion for cell culture and animal tissues (25). Also, HSP70 
helps proteins to be transported in cells and has a function 
in the folding of proteins synthesized within the cell and 
it is responsible for the destruction of unstable proteins as 
well as preventing protein aggregation and it also helps 
protein folding refold when damaged and apoptosis (26). 
In our study, in addition to investigating the preva-
lence of viral infections (HBV and HCV), one of the 
major problems encountered in hemodialysis patients 
receiving dialysis treatment due to chronic renal failure, 
we also aimed to evaluate the effect of infection on oxida-
tive stress and protein oxidation. For this purpose, 3-NT, 
TWEAK and HSP70 levels were investigated in the con-




Ethical approval for the study was obtained from local 
ethics committee (University of OMU Protocol No. 
107/2012). Two hundred thirty-five patients receiving 
hemodialysis therapy due to chronic renal failure in Co-
rum private dialysis centers were involved in the study. 
The numbers of patients with HBV and HCV infections 
and non-hepatitis receiving hemodialysis treatment in-
cluded in the study were based on the power analysis. The 
patients were classified into different groups based on the 
presence of viral coinfections as well.. Serum samples of 
235 patients receiving hemodialysis treatment due to 
chronic renal failure and 25 individuals as healthy control 
group were included in the study. Patients included in this 
analysis ranged in age from 25 to 65 years old, with a 
median age of  45. Serum was obtained by centrifugation 
of whole blood at 3000 rpm for 10 min and aliquots were 
stored at −80 °C until assayed. 
Diagnosis of HVC and HBV infections 
HBV and HCV positivity were determined by sero-
logical ELISA method. HBsAg ELISA kits (ABOTT 
PRISM HBsAg, USA) for HBV and Murex anti-HCV 
ELISA kits (ABBOTT murex, South Africa) for HCV 
were used.
Protein Damage Index: Determination of 
3-nitrotyrosine levels 
Determination of 3-NT levels, the protein damage 
indicator in the serum sample of patients and healthy 
individuals included in the study, was done using HPLC 
(Immuchrom, Haasen, Germany) kit in HPLC system 
(High-Performance Liquid Chromatography). 
Determination of TWEAK and HSP70 
levels 
High-sensitivity ELISA kit was used to determine the 
level of the Human TWEAK instant and Human soluble 
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HSP70 (Bendermed Diagnostic System, eBioscience, 
Austria, Avicer to, eBioscience, Inc., respectively). 
Statistical analysis 
Statistical analysis was performed using SPSS 20.0 
software (IBM SPSS Inc. Chicago, IL, USA). All mea-
surements were taken in triplicate. Data are reported as 
means± standard distribution (SD). After assessing the 
normality distribution (Shapiro-Wilk test) and homoge-
neity of variances, parametric t-test and ANOVA were 
used. In cases where these assumptions were not met, 
non-parametric Mann Whitney-U and Kruskal Wallis 
H-tests were used for comparison of differences between 
means. The critical significance level for the statistical 
tests performed was set at 0.05.
RESULTS
HBV and HCV positivity were investigated in all 
samples through ELISA method. According to the re-
sults, the rate of HBV was 22.5 % (53/235), the rate of 
HCV was 10.6 % (25/235), while 66.8 % (157/235) of 
patients were not infected with HCV or HBV . 
Evaluation of 3-NT 
The level of 3-nitrotyrosine, which is the protein dam-
age indicator, was found to be significantly higher non-
hepatitis patients, hepatitis B and hepatitis C patients 
receiving hemodialysis treatment than the control group 
(p<0.05). 3-NT values of patients with HCV in pre-he-
modialysis were found higher than those of HBV and 
non-hepatitis group. Although a significant decrease 
could be observed on post-dialysis when the pre and post-
dialysis 3-NT values were compared in all samples, still 
the values obtained were higher compared with the con-
trol group as indicated in Table 1 and Figure 1. 
Table 1. 3-NT values (μg/L) of non-hepatitis, HBV and HCV pa-
tients receiving hemodialysis treatment and control group




Control 25 13.08  ± 4.65 11.16 – 15.00
HBV
Pre-HD 25 124.62 ± 33.65* 110.73 – 138.51
Post-HD 25 21.72 ± 7.46* 18.64 – 24.80
HCV
Pre-HD 25 257.22 ± 25.05* 246.88 – 267.57
Post-HD 25 34.80 ± 17.25* 27.68 – 41.92
Non-Hepatitis
Pre-HD 25 211.16 ± 35.88* 196.35 – 225.97
Post-HD 25 42.03 ± 16.12* 35.37 – 48.68
HD; Hemodialysis
Values are expressed as mean ± S.D.
* Statistical significance level was determined as p <0.05 when both 
control and intra-group comparisons were made. (p=0.000 for HBV, 
HCV and non-hepatitis)
Figure 1. 3-NT levels, the protein damage index of non-hepatitis, hepatitis B and hepatitis C patients receiving hemodialysis treatment and 
control group.
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Evaluation of TWEAK
TWEAK values in non- hepatitis and HBV patients 
receiving hemodialysis therapy were found to be signifi-
cantly higher compared with controls (p<0.05). Although 
a significant decrease could be observed in non-hepatitis 
and HBV patients groups in post-dialysis when the pre 
and post-dialysis values were compared, the values could 
still be observed to be above the control group. However, 
unlike the other two groups, an increase in the TWEAK 
values of HCV patients on post-dialysis was determined. 
TWEAK values of all groups were given in Table 2 and 
Figure 2.
Evaluation of HSP-70
The HSP-70 values were found to be higher in non-
hepatitis, HBV and HCV patients receiving hemodialysis 
therapy than those of control group. When pre and post-
dialysis values are compared, a minimal increase in post-
dialysis among HBV, HCV and non-hepatitis patient 
groups was observed (Table 3, Figure 3). Statistical sig-
nificance level was determined as p<0.05 when both con-
trol and intra-group comparisons were made. But when 
the intra-group comparison was made, the statistical sig-
nificance level was determined as p>0.05 only on HBV 
group.
DISCUSSION
Hemodialysis is an effective treatment for most patients 
with renal failure and an alternative for kidney transplan-
tation, thereby improving the quality of life of the patient 
with adequate dialysis and even prolongs the lifespan (27). 
However, among the most important factors leading to an 
increase in mortality rate and restricting the quality of life 
Table 2. TWEAK values (pg/ml) of non-hepatitis, HBV and HCV 
patients receiving hemodialysis treatment and control group 




Control 25 335.7  ± 49.2 315.4 – 356.0
HBV
Pre-HD 25 773.8 ±452.6* 587.0 – 960.7
Post-HD 25 380.8 ± 68.8* 352.4 – 409.2
HCV
Pre-HD 25 181.2 ±54.9* 158.6 – 203.9
Post-HD 25 462.2 ±140.7* 404.0 – 250.2
Non-Hepatitis
Pre-HD 25 989.2 ± 234.6* 892.4 – 1086.1
Post-HD 25 429.1 ±104.3* 386.0 – 472.1
HD; Hemodialysis
Values are expressed as mean ± S.D.
* Statistical significance level was determined as p <0.05 when both 
control and intra-group comparisons were made. (p=0.016 for HBV, 
p=0.000 for HCV and non-hepatitis)
Figure 2. TWEAK levels of non-hepatitis, hepatitis B and hepatitis C patients receiving hemodialysis treatment and control group
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in dialysis patients during the dialysis are viral diseases. In 
particular, HBV and HCV are serious public health prob-
lems in the world; moreover, patients with chronic kidney 
disease are exposed to these infections at a very high rate 
(7, 8). The compromised immune systems of the dialysis 
patients with dialysis might lead to other disorders in 
other body functions. Vascular calcification and oxidative 
stress are widely encountered especially among patients 
receiving hemodialysis developing end-stage renal disease 
(ESRD). In addition to investigating the prevalence of 
viral infections (HBV and HCV), one of the major prob-
lems encountered in hemodialysis patients receiving di-
alysis treatment due to chronic renal failure, we also aimed 
to evaluate the effect of infection on oxidative stress and 
protein oxidation in this patient group through various 
parameters. For this purpose, by determining the 3-NT, 
TWEAK and HSP70 levels, these levels were compared 
both with the control and patient groups. The level of 
3-NT, the oxidative stress indicator, in these patients was 
also investigated by Erdur et al. to determine the relation-
ship between coronary artery calcification and oxidative 
stress in peritoneal dialysis and hemodialysis patients and 
it was found that the level of nitrotyrosine was higher 
compared to healthy individuals (28). Koleganova et al. 
immunohistochemically determined the level of TNF-alpha 
and nitrotyrosine in aortic samples of ESRD and control 
group. ESRD patients on TNF-alpha and nitrotyrosine lev-
els were found to be significantly higher compared to the con-
trol group (29). In the results part of the study in which Köse 
et al aimed to determine the effects of hemodialysis and peri-
toneal dialysis treatments on of oxidative and nitrosative stress 
markers, they concluded that pre and post hemodialysis high 
plasma 3-NT levels could indicate a significantly increased 
risk for nitrosative  tissue damage in these patients. Kose et 
Table 3. HSP –70 values (pg/ml) of non-hepatitis, HBV and HCV 
patients receiving hemodialysis treatment and control group





Control 25 3.3 ± 0.3 3.2 – 3.4
HBV**
Pre-HD 25 11.8 ±2.6* 10.7 – 12.9 *
Post-HD 25 12.6 ±3.9* 11.0 – 14.5 *
HCV
Pre-HD 25 9.7 ± 1.0* 9.3 – 10.2 *
Post-HD 25 10.8 ±1.7* 10.1 – 11.6 *
Non-Hepatitis
Pre-HD 25 9.9 ±1.3* 9.4 –10.4 *
Post-HD 25 10.8 ± 1.4* 10.2 –11.4 *
HD; Hemodialysis
Values are expressed as mean ± S.D.
* Statistical significance level was determined as p <0.05 when both 
control and intra-group comparisons were made. (p=0.011 for HCV 
and p=0.031 for non-hepatitis)
** But when the intra-group comparison was made, the statistical 
significance level was determined as p> 0.05 only on HBV group. 
(p=0.751 for HBV)
Figure 3. HSP –70 levels of non-hepatitis, hepatitis B and hepatitis C patients receiving hemodialysis treatment and control group
Emre Avci et al. HBV and HCV in HEMODIALYSIS
38 Period biol, Vol 120, No 1, 2018.
al, in their study, indented to determine the effect of he-
modialysis and peritoneal dialysis treatments on oxidative 
and nitrosative stress markers revealed that high presence 
of 3-NT levels pre and post hemodialysis indicate signifi-
cantly increased the risk for nitrosative tissue damage in 
these patients (30). It was found in a study carried out by 
Proddi et al that 3-NT levels in CKD and ESRD patients 
were significantly higher compared to healthy subjects 
(31). In a study by Qian et al which aimed to investigate 
the relationship between the level of protein damage in-
dicator 3 NT and mortality in patients receiving treat-
ment due to kidney damage. Therefore, 90-day mortality 
rates of patients treated for kidney damage and 3-NT 
levels were recorded and compared. The level of 3-NT in 
patients with kidney damage was found significantly 
higher compared to healthy control subjects. It was also 
found that high 3 -NT levels in patients are also propor-
tional to high mortality rates (32). Oxidative stress is one 
of the potential biochemical mechanisms of chronic viral 
pathogenesis. In his study  In an another study, Namidu-
ru et al measured malondialdehyde, myeloperoxidase and 
nitrotyrosine levels in chronic HBV and HCV patients in 
order to determine the level of oxidative stress. No statisti-
cally significant difference between patients with hepatitis 
and control group was observed in nitrotyrosine levels. 
The data obtained from this study has shown that there is 
oxidative stability in patients with chronic viral disorders 
(33). In our study, 3 NT levels were found statistically 
significantly higher in pre dialysis of non-hepatitis, HBV 
and HCV patients receiving hemodialysis treatment sta-
tistically significantly higher than the control group. De-
spite the reduction in 3-NT levels post dialysis they still 
did not reach the value of healthy individuals. Considering 
the values obtained from the study, it has been established 
that protein oxidation caused by 3-NT and a cytocidal 
effect was higher HCV patients among other patient 
groups. In recent years, although it has been known that 
TWEAK, a glycoprotein found in the TNF superfamily, 
has a relation with atherosclerosis, endothelial dysfunction 
and mortality in renal and non-renal patients, the results 
obtained vary from each other. Increased levels of 
TWEAK are observed in clinical conditions caused by 
inflammatory events, while TWEAK level decreases in 
atherosclerosis, which indicates that the event could be 
different depending on the interaction in receptor levels 
(34). In our study, the increase and reduction in TWEAK 
levels of HBV and HCV patients compared to the control 
are thought to be caused by receptor difference which 
plays a significant role in the viral interaction. Kralish et 
al in a study determined TWEAK levels in healthy control 
group, TWEAK levels in hemodialysis patients also in 
diabetic patients on hemodialysis therapy and found that 
TWEAK levels significantly reduced in diabetic patients 
receiving hemodialysis treatment and also concluded that 
TWEAK could be a risk factor for atherosclerosis (35). 
Yilmaz et al. studied how patients with non-diabetic 
chronic renal failure undergo changes in TWEAK levels 
in different stages and also investigated whether there is a 
relationship between TWEAK levels and endothelial dys-
function. It was found that as the stage of renal failure 
increases, there is an increase in endothelial dysfunction 
as opposed to the decrease in TWEAK level and it was 
also concluded that TWEAK is independent of endothe-
lial dysfunction (36). In our study, it was observed that 
the high TWEAK value pre-dialysis, which is a marker of 
inflammation, decreased the following dialysis in HBV 
and non-infective patient groups, but it was determined 
not to be enough. As for HCV patients, while their pre 
dialysis TWEAK levels were lower compared to healthy 
subjects, these values increased post dialysis and passed 
the TWEAK values of healthy subjects. Inflammation in 
HCV patients was observed to increase rapidly with di-
alysis. Another parameter associated with oxidative stress 
is heat shock protein HSP70 and it can also be detected 
in diseases such as tissue, cell or serum levels of cardiovas-
cular diseases, diabetes or diseases such as hyperlipidemia, 
and obesity (37). Yabunak et al found that HSP70 levels 
of diabetic patients in mononuclear cells which were mea-
sured by Western blot method was higher than in healthy 
controls, but stated that it has no connection with HbA1c 
and fasting blood glucose (38). In spite of various diseases 
in the literature to be working with a group of diseases 
with similar levels of HSP70, it was determined and found 
to be higher in the presence of oxidative stress. In the lit-
erature reviews done, although there was no study with 
similar disease groups, HSP70 levels were detected in 
some diseases and found to be higher in the presence of 
oxidative stress (26, 39, 40). In our study, a statistically 
significant increase pre and post dialysis in HSP70 levels 
of the patient groups and the HSP70 levels belonging to 
the healthy control group was observed. However, a sta-
tistically significant change was determined between the 
groups.
CONCLUSIONS
Renal failure is a disease that manifests itself in the 
deterioration of the essential functions of the kidneys that 
cause damage to the individual at a significant level, which 
is accompanied by a decrease in glomerular filtration value. 
Although this damage, which occurs in the kidneys, is 
tried to be alleviated by dialysis treatment, it also increases 
the oxidative stress and immunity in the patients. 
Viral diseases are frequently seen in patients undergo-
ing hemodialysis treatment. Increased viral load in these 
patients increases the oxidative burden in the organism 
with renal failure. 
In our study, 3-NT, TWEAK and HSP 70 values were 
higher in patients without hepatitis compared to the con-
trol group, indicating that oxidative stress and immunity 
increased in patients and that they could not be suffi-
ciently reduced by dialysis treatment. In addition to di-
alysis, the presence of HBV alone and HCV alone in these 
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patients affects different levels of oxidative stress and im-
munity in patients. The presence of HCV alone increased 
the levels of 3-NT and HSP in the patients and caused a 
decrease in the TWEAK values. 
To prevent the increase of inflammation and oxidative 
stress in hemodialysis patients or to keep it under control, 
investigating certain parameters such as TWEAK, 3-NT 
and HSP70 from time to time is of great importance in 
terms of minimizing the level of risk for many diseases 
such as cardiovascular diseases. 
Infection also increases the burden on oxidative stress 
and ımmunity system in these patients. This study em-
phasizes that the important of infection in dialysis pa-
tients who have a high mortality and morbidity rate. 
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